title: A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.
abstract: OBJECTIVE
  A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.
  
  
  OBJECTIVE
  
  
  
  OBJECTIVE
  1. To study the MACE and in stent and In-segment Loss at Six Months (in a pre selected group of 50 patients).
  
  
  OBJECTIVE
  1. Clinical and procedural success.
  
  
  METHODS
  This is a prospective, open label, single-arm, multicenter (16 sites), post marketing observational study enrolling patients implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) in routine clinical practice in India. A total of 200 Patients of coronary Artery Disease (CAD) implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) were enrolled. Clinical assessments were done at 30 days, 180 days and at 1, 2 years either telephonically or office visit. A cohort of 50 pre-selected patients were followed up for angiographic evaluation at 180 days.
  
  
  RESULTS
  MACE at 12 month of follow up was 1.71%.Late lumen loss, in segment was 0.14 and in stent was 0.10 mm at 6 month of follow-up. TLR was required only in 2 patients.
  
  
  CONCLUSIONS
  Superia stent is as safe as other biodegradable polymer stent in the market and time has come for biodegradable polymer stent with thin struts.
authors: Department of Intervention Cardiology, Medanta the Medicity, Gurgaon, India. Electronic address: praveen.chandra@medanta.org.
authors: Praveen
authors: P
authors: Chandra
authors: Department of Intervention Cardiology, Medanta the Medicity, Gurgaon, India.
authors: Tarun
authors: T
authors: Kumar
keywords: India; Post market surveillance; Superia sirolimus eluting stent
references: Circulation. 2006 Nov 14;114(20):2148-53
references: 17060388
references: Circ J. 2006 Nov;70(11):1367-71
references: 17062955
references: Drug Saf. 2009;32(9):749-70
references: 19670915
references: Minerva Cardioangiol. 2009 Oct;57(5):567-84
references: 19838148
references: JACC Cardiovasc Interv. 2009 Oct;2(10):977-85
references: 19850258
references: Circ Cardiovasc Interv. 2009 Aug;2(4):339-47
references: 20031737
references: Nat Rev Cardiol. 2010 Apr;7(4):194-203
references: 20195268
references: BMJ. 2013;347:f6625
references: 24212107
references: N Engl J Med. 2002 Jun 6;346(23):1773-80
references: 12050336
references: N Engl J Med. 2003 Oct 2;349(14):1315-23
references: 14523139
references: N Engl J Med. 2004 Jan 15;350(3):221-31
references: 14724301
references: Circulation. 2006 Jan 3;113(1):156-75
references: 16391169
references: N Engl J Med. 2006 Feb 2;354(5):483-95
references: 16452560
references: Am J Cardiol. 2006 Feb 15;97(4):506-11
references: 16461047
references: Circulation. 2006 Aug 22;114(8):798-806
references: 16908773
references: Am J Cardiol. 2006 Oct 1;98(7):918-22
references: 16996874
references: Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1500-10
references: 17510464